Grunenthal GmbH:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C0464)・商品コード:DATA904C0464
・発行会社(調査会社):GlobalData
・発行日:2018年7月
・ページ数:68
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Venture Financing 18
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Partnerships 22
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children’s Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Licensing Agreements 38
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Equity Offering 47
Thar Pharma Postpones IPO for USD50 Million 47
Asset Transactions 49
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Acquisition 53
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH – Key Competitors 57
Grunenthal GmbH – Key Employees 58
Grunenthal GmbH – Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Recent Developments 62
Strategy And Business Planning 62
May 10, 2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 62
Corporate Communications 63
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 63
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 64
Government and Public Interest 65
Nov 16, 2017: Research Consortium led by Grünenthal receives € 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 65
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients’ Lives – EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 66
Product News 67
Jul 07, 2017: Grünenthal Group: Launch of the Project – Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Thar Pharma Postpones IPO for USD50 Million 47
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH, Key Competitors 57
Grunenthal GmbH, Key Employees 58
Grunenthal GmbH, Other Locations 59
Grunenthal GmbH, Subsidiaries 59

List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

★調査レポート[Grunenthal GmbH:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C0464)販売に関する免責事項を必ずご確認ください。
★調査レポート[Grunenthal GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆